

# PAM-flexible dual base editor-mediated random mutagenesis and self-activation strategies to improve CRISPRa potency

Cia-Hin Lau,<sup>1,2</sup> Siping Huang,<sup>1,2</sup> Raymond H.W. Lam,<sup>1</sup> and Chung Tin<sup>1</sup>

<sup>1</sup>Department of Biomedical Engineering, City University of Hong Kong, Room P6416, Yeung Kin Man Academic Building, 83 Tat Chee Avenue, Kowloon Tong, Hong Kong, SAR, China

**VP64 is the smallest transactivation domain that can be packaged together with the sgRNA into a single adeno-associated virus (AAV) vector. However, VP64-based CRISPRa often exerts modest activation to the target gene when only one sgRNA is used. Herein, we used PAM-flexible dual base editor-mediated mutagenesis and self-activation strategies to derive VP64 variants with gain-of-function mutations. First, we generated an HEK293FT transgenic clone to stably expressing pTK-CRISPRa-GFP. The sgRNA of CRISPRa was designed to target the TK promoter, thereby allowing self-activation of CRISPRa-GFP. Base editors were then used to randomly mutagenesis VP64 in this transgenic cell. VP64 with enhanced potency would translate into increment of GFP fluorescence intensity, thereby allowing positive selection of the desired VP64 mutants. This strategy has enabled us to identify several VP64 variants that are more potent than the wild-type VP64. ΔCRISPRa derived from these VP64 variants also efficiently activated the endogenous promoter of anti-aging and longevity genes (*KLOTHO*, *SIRT6*, and *NFE2L2*) in human cells. Since the overall size of these ΔCRISPRa transgenes is not increased, it remains feasible for all-in-one AAV applications. The strategies described here can facilitate high-throughput screening of the desired protein variants and adapted to evolve any other effector domains.**

## INTRODUCTION

CRISPR activator (CRISPRa) offers several advantages over nuclease-based genome editing, such as restoring normal gene expression and correct gene misregulation without altering the underlying DNA sequence and inducing DNA damage.<sup>1,2</sup> Moreover, CRISPRa allows physiological or near-physiological expression of target endogenous genes by modulating gene regulatory elements (e.g., promoter and enhancer).<sup>3</sup> Importantly, CRISPRa can upregulate the most relevant splice variants of the targeted gene even when the function of this splice variant is unknown. In contrast, the physiologically relevant splice variants could be missed if cloning expression cassette from the cDNA for ectopic overexpression.<sup>3</sup> Similarly, overexpressing a certain splice variant from the open reading frame may result in missing other physiologically relevant splice variants. Protein overexpression can also be harmful to the cell since the production of the protein amount is uncontrollable and can upset the

balance in protein complexes. Ectopic overexpression often uses strong exogenous promoters that can result in supraphysiological expression levels. It is also a great challenge to clone multiple genes, a long gene, a highly repetitive sequence, or GC-rich genes into the viral vector for overexpression.

Adeno-associated virus (AAV) has become an increasing popular viral vector for therapeutic gene transfer *in vivo*. Besides being non-pathogenic to humans, AAV elicits a very mild immune response *in vivo*, and its genetic material is rarely integrated into the host genome.<sup>4</sup> Also, AAV is attractive for *in vivo* applications owing to its high efficacy of viral delivery and transduction.<sup>5</sup> Apart from dividing cells, AAV is capable of infecting non-dividing cells, such as postmitotic neurons in the central nervous system and somatic tissues in the adult animals. AAV provides long-term transgene expression in these quiescent cells due to its ability to replicate epichromosomally by forming stable concatemers. However, owing to the limited packaging capacity of AAV, careful design is required to package an all-in-one CRISPRa for *in vivo* target gene activation.

We have recently developed an all-in-one CRISPRa that can be packaged into a single AAV vector for targeted gene activation *in vitro* and *in vivo*.<sup>6</sup> In addition, this CRISPRa could be efficiently delivered by our newly engineered AAV1-PHP.B variant for targeted transgene activation in the mouse brain via systemic administration. In our design, CRISPRa is a fusion of catalytically inactive SaCas9 (dSaCas9)<sup>7</sup> and VP64 transcriptional activator domain,<sup>8–10</sup> and linked to truncated regulatory elements. Owing to the limited packaging capacity of AAV, only one single guide RNA (sgRNA) can be packaged together with the dSaCas9-VP64 into an AAV vector. Despite this CRISPRa vector being minimal in size, its transgene expression and functionality were not compromised. On the other hand, AAV1-PHP.B variant

Received 21 July 2021; accepted 25 May 2022;  
<https://doi.org/10.1016/j.omtm.2022.05.005>.

<sup>2</sup>These authors contributed equally

**Correspondence:** Chung Tin, PhD, Department of Biomedical Engineering, City University of Hong Kong, Room P6416, Yeung Kin Man Academic Building, 83 Tat Chee Avenue, Kowloon Tong, Hong Kong, SAR, China.

**E-mail:** chungtin@cityu.edu.hk



was engineered by inserting a 7-mer PHP.B peptide on an AAV1 capsid.<sup>6</sup> PHP.B peptide was previously identified through an *in vivo* AAV9 capsid library screen in adult mice.<sup>11</sup> PHP.B peptide insertion to the AAV9 capsid significantly enhanced the blood-brain-barrier crossing ability and broadened biodistribution and transduction of AAV9 in the adult mouse central nervous system. Thereafter, these enhancement properties of AAV9-PHP.B were similarly reported in many other studies.<sup>12–14</sup> As seen for AAV9, we demonstrated that this enhanced blood-brain-barrier crossing of PHP.B modification could be extended to AAV1. Our AAV1-PHP.B can efficiently deliver this CRISPRa to cross the blood-brain barrier and be taken up by the brain tissue upon lateral tail vein injection in mice.<sup>6,11</sup>

Despite the attractiveness of these engineered CRISPRa and AAV tools, our existing AAV-CRISPRa system requires co-delivery of several different AAV vectors to simultaneously express multiple sgRNAs for effective endogenous gene activation. This is because only one sgRNA can be packaged together with the dSaCas9-VP64 into this all-in-one CRISPRa construct. A single AAV vector platform is desired because it ensures co-delivery of both dSaCas9-VP64 and sgRNA into each cell. However, VP64-based CRISPRa often exerts modest activation to the target gene when only one sgRNA is employed. Although a number of recently reported activator domains (e.g., VPR,<sup>15</sup> TET1,<sup>16</sup> P300,<sup>17</sup> and PRDM9<sup>18</sup>) are more potent than the VP64 activator, their large size has ruled out the possibility of co-packaging them with dSaCas9 and its sgRNA into a single AAV vector. Since VP64 is the only transactivation domain that can be selected to construct CRISPRa for application of a single AAV vector platform, here, we attempted to use PAM-flexible dual mutations base editor-mediated mutagenesis and self-activation strategies for enhancing VP64 potency.

To derive VP64 variants with gain-of-function mutations, we first generated a HEK293FT clone to stably express pTK-CRISPRa-GFP via CRISPR/Cas9-mediated homologous recombination. The sgRNA of CRISPRa was designed to target the TK promoter, thereby allowing self-activation of CRISPRa-GFP. Diverse VP64 mutants were then generated by random mutagenesis of the VP64 in this transgenic cell using different PAM-flexible dual base editors with multiple sgRNAs. Next, we screened and identified the VP64 variants with gain-of-function mutations by constructing various pCMV- $\Delta$ CRISPRa to perform luciferase reporter assay and targeting endogenous genes *in vitro*. Finally,  $\Delta$ CRISPRa with the most potent VP64 mutant was packaged into the AAV1-PHP.B vector for activating target endogenous genes *in vitro*. The strategies described here can minimize complexity and facilitate high-throughput screening of the desired protein variants. Thus, it can be potentially adapted to evolve any other effector domains and CRISPR components.

## RESULTS

### Generation of an HEK293FT transgenic clone to stably express pTK-CRISPRa-GFP

To generate a transgenic clone stably expressing pTK-CRISPRa-GFP, we co-transfected CRISPR-Cas9 targeting the *AAVS1* site and donor pTK-dSaCas9-VP64-2A-GFP-pU6-sgRNA harboring two flanking


*AAVS1* homology arms into the HEK293FT cells (Figure 1A). Upon CRISPR-Cas9-induced DNA double-strand breaks, the donor vector was integrated into the *AAVS1* locus via homologous recombination. After 1 week of co-transfection, the GFP-expressing cells were sorted and expanded on a 96-well plate. Genomic DNA from each single-cell derived clone was then extracted for PCR genotyping. Three pairs of primer were used for PCR genotyping (Figure 1B). Primer pair 3 (P3) was used to confirm site-specific integration of a donor pTK-CRISPRa-GFP at the *AAVS1* locus, while the other two primer pairs (P1 and P2) were used to ensure insertion of full-length pTK-CRISPRa-GFP. PCR genotyping with these three pairs of primer confirmed targeted integration of the full-length pTK-CRISPRa-GFP sequences at the genomic *AAVS1* locus in HEK293FT C2.8 clone.

### Enhanced CRISPRa function by VP64 mutagenesis

We performed VP64 mutagenesis in pTK-CRISPRa-GFP expressing HEK293FT C2.8 clone using PAM-flexible (SpRY<sup>19</sup> and nCas9-NG<sup>20</sup>) and dual base editors (A&C-BE<sub>max</sub>-nCas9<sup>21</sup> and TadA-nCas9-NG-CD<sub>A1</sub><sup>20</sup>), as well as dCas9-based base editors (ABE7.10,<sup>22</sup> BE3,<sup>22</sup> ABE<sub>max</sub>,<sup>23</sup> AncBE4<sub>max</sub>,<sup>23</sup> BE4<sub>max</sub>,<sup>23</sup> and AID<sup>24</sup>). Base editor was used because it enables clean mutational knockin by direct conversion of nucleotides in genomic DNA without inducing double-strand DNA breaks and generating indel mutations.<sup>22,25</sup> Adenine base editor (e.g., ABE7.10<sup>22</sup> and ABE<sub>max</sub><sup>23</sup>) mediates the direct conversion of adenine to inosine, which eventually leads to an A-to-G (or T-to-C) substitution. Meanwhile, cytidine base editor (e.g., BE3,<sup>22</sup> AncBE4<sub>max</sub>,<sup>23</sup> and BE4<sub>max</sub><sup>23</sup>) mediates the direct conversion of cytidine to uridine, which eventually leads to a C-to-T (or G-to-A) substitution. AID directs somatic hypermutation to a given genomic locus by deamination of cytosine to uracil, which eventually converts cytidines or guanines to any other three bases at the desired loci.<sup>24</sup>

However, if using dCas9-based base editors, only four target sites with adjacent PAM sequences can be designed on VP64 transgene due to the PAM sequence constraints. To enable exhaustive discovery of VP64 with gain-of-function mutations, we further employed PAM-flexible dual base editors for maximizing the diversity of VP64 mutants generated. SpRY<sup>19</sup> and nCas9-NG<sup>20</sup> have more relaxed PAM requirements than the SpCas9. The PAM requirement of nCas9-NG is NG, while SpRY is a near-PAMless SpCas9 variant that can target NRN and to a lesser extent NYN PAMs. Using these PAM-flexible base editors, we were able to design 22 sgRNAs to target every sequence on the VP64 transgene (Figure 2A). To expand the range of DNA alterations, dual base editors were used to allow concurrent adenine and cytosine editing.<sup>20,21</sup>

One week after the transfection of base editors into this HEK293FT C2.8 clone, the brightest GFP-positive cells were sorted for single-cell cloning (Figure 2B). We speculate that the introduction of gain-of-function mutations to the VP64 transgene can improve the activation potency of VP64, thereby improving CRISPRa function and increasing GFP expression. As expected, only a very small portion of cells displayed higher GFP expression than the original HEK293FT C2.8 clone upon random mutagenesis of the VP64 transgene. These brightest



### Figure 1. Generation of a HEK293FT transgenic clone stably expressing pTK-CRISPRa-GFP

(A) Targeted integration of a donor pTK-CRISPRa-GFP into the genomic AAVS1 locus via CRISPR-Cas9-mediated homologous recombination. (B) Confirming site-specific integration of the full-length pTK-CRISPRa-GFP sequences at the genomic AAVS1 locus by PCR genotyping. AAVS1, adeno-associated virus integration site 1; GFP, green fluorescent protein; pTK, thymidine kinase promoter.

tween two sgRNA target sites. To minimize this deletion issue, we also designed multiple sgRNAs of SpRY or nCas9-NG that are targeted only on one of the DNA strands (sense or antisense).

### Functional validation of the VP64 variants

All the newly identified VP64 mutations were functionally validated by performing luciferase reporter assays. In this episomal reporter assay, AAV-compatible CRISPRa (CMV-dSaCas9-ΔVP64) derived from different VP64 variants was constructed. The size of the CRISPRa is within the AAV packaging capacity (<4.7 kb). In this assay, each of this ΔCRISPRa plasmid was co-transfected with the pTK-Ren luciferase plasmid into the wild-type HEK293FT cells. The guide sequence of ΔCRISPRa was designed to target the TK promoter that drives the expression of the Renilla luciferase gene. To


identify the most efficient sgRNA for CRISPRa, we designed eight sgRNAs to target the TK promoter (Figure 4A). From these eight sgRNAs, sgRNA-7 exerted the strongest Renilla luciferase activity. Therefore, sgRNA-7 was selected for constructing ΔCRISPRa plasmids and testing in subsequent luciferase assay (Figure 4B).

Two days after the plasmid transfections, the luciferase activities induced by the ΔCRISPRa were quantified and compared. Compared with CRISPRa with the wild-type VP64, our luciferase reporter assays revealed a higher luciferase activity induced by CRISPRa bearing VP64 variants such as A2, S4, M10, CA8.15, and CA10.11 (Figure 4B). Among these VP64 variants, CA10.11, A2, and S4 consistently showed the highest luciferase activity, therefore, these three VP64 variants were selected for activating endogenous genes and packaging into the AAV vector.

In the subsequent validation, pCMV-ΔCRISPRa derived from CA10.11, A2, and S4 were used to target and activate the promoter of target endogenous genes (*KLOTHO*, *SIRT6*, and *NFE2L2*) in human HEK293FT cells. We also tested ΔCRISPRa bearing both A2 and CA10.11 mutations. These endogenous genes were targeted for several reasons. Previous studies have shown that the promoter of

GFP-expressing cells were then isolated for culturing and expanding. A large portion of cells has reduced GFP expression owing to the introduction of deleterious mutations to the VP64 transgene. In this case, CRISPRa no longer can self-activate its promoter to express the GFP. To support this notion, we added additional control by designing the CRISPR-Cas9 to knock out the sgRNA of this CRISPRa in the HEK293FT C2.8 original clone. Upon knockout, CRISPRa no longer can activate the TK promoter in this clone, thereby decreasing the GFP fluorescent intensity. Thus, a fluorescent density plot similar to VP64 mutagenesis is observed. This knockout experiment strongly proved that this single sgRNA was enough to enable CRISPRa to activate its TK promoter, thereby confirming our self-activation strategy is functional.

After single-cell sorting and expansion, we successfully derived 86 clones with GFP expression higher than the original HEK293FT C2.8 clone. We then performed PCR to amplify the VP64 sequence from the genomic DNA of each clone for sequencing the full-length VP64 transgene. From these 86 clones, we identified 19 variants of VP64 (Figures 3 and S1). Apart from substitution mutations, designing guide sequences to target multiple sites on VP64 transgene would lead to the deletion of the intervening segment be-



**Figure 2. Enhanced CRISPRa function by VP64 mutagenesis**

(A) sgRNA target sites of base editor on VP64 transgene. Arrows indicate the sense or antisense orientation of sgRNAs designed to recognize target DNA sequences. (B) Sorting of VP64 mutagenesis cells. Multiple sgRNAs and various base editors were used to target and for mutagenesis of the VP64 transgene in the HEK293FT C2.8 clone. The brightest GFP-positive cells in the gate region are sorted for single-cell cloning, followed by PCR genotyping and DNA sequencing. Density plots are shown, with the highest density cells in the red areas. GFP, green fluorescent protein; SSC, side scatter.

### Substitution mutations

VP64-WT GRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLIN  
 VP64-A2 GRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLIN  
 VP64-A3 GRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLIN  
 VP64-D1 GRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMVGSALDDFDLDMLIN  
 VP64-D4 GRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMVGSALDDFDLDMLIN  
 VP64-M6 GRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMVGSALDDFDLDMLIN  
 VP64-M12 GRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMVGSALDDFDLDMLIN  
 VP64-S1 GRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMVGSALDDFDLDMLIN  
 VP64-S13 GRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMVGSALDDFDLDMLIN  
 VP64-CA8.1 GRADALDDFDLDMVGSALDDFDLDMLGSDALDDFDLDMVGSALDDFDLDMLIN  
 VP64-CA8.15 GRADALDDFDLDMVGSALDDFDLDMLGSDALDDFDLDMVGSALDDFDLDMLIN  
 VP64-CA10.11 GRADALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMLIN  
 VP64-CA18.14 GRADALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMLIN  
 A2+CA10.11 GRADALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMLIN

### Deletions

VP64-WT GRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLIN  
 VP64-M3 GRADALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMLIN  
 VP64-M5 GRADALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMLIN  
 VP64-M10 GRADALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMLIN  
 VP64-S2 GRADALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMLIN  
 VP64-S4 GRADALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMLIN  
 VP64-S9 GRADALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMLIN  
 VP64-S11 GRADALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMVGSALDDFDLDMLIN

#### Base editors used:

A: dCas9-ABE7.10 + dCas9-BE3

AC: A&C-BE<sub>max</sub>-nCas9

CA: CBE4<sub>max</sub>-SpRY + ABE<sub>max</sub>-SpRY

D: dCas9-AID

M: dCas9-ABE<sub>max</sub> + dCas9-AncBE4<sub>max</sub>

S: dCas9-ABE7.10 + dCas9-BE3 + dCas9-ABE<sub>max</sub> + dCas9-AncBE4<sub>max</sub> + dCas9-BE4<sub>max</sub> + dCas9-AID

T: TadA-nCas9-NG-CDA1

*KLOTHO* gene could be robustly activated by CRISPRa (dSpCas9-VP64) in HEK293T cells.<sup>26</sup> On the other hand, *SIRT6* and *NFE2L2* genes were targeted because our qPCR data confirmed that these two genes are expressed in HEK293FT cells. *KLOTHO* is a well-known longevity gene and it encodes membrane-bound and secreted forms of Klotho protein. The secreted form (circulating hormone) displays an important role in anti-aging and longevity.<sup>27,28</sup> Overexpression of *Klotho* gene could extend life span in mice by inhibiting insulin and insulin-like growth factor 1 signaling, while a defect in *Klotho* gene expression in mice would lead to aging and age-related phenotypes.<sup>27</sup> On the other hand, *SIRT6* encodes Sirtuin 6 that functions in DNA repair and telomere maintenance.<sup>29</sup> Knockout of *Sirt6* shortens lifespan and causes premature aging,<sup>30,31</sup> while overexpression of *Sirt6* could prolong the life span in male mice.<sup>32</sup> Meanwhile, *NFE2L2* encodes the Nrf2 transcription factor that can regulate the expression of a large number of cytoprotective genes to defend against oxidative stress.<sup>33</sup> In fact, many pharmacological drugs in pre-clinical testing have been developed to target and activate *NFE2L2* for the treatment of various age-related human diseases.<sup>34,35</sup> By designing sgRNAs to target three different sites on each endogenous promoter, we found that ΔCRISPRa particularly CA10.11 (120% *Klotho* and 38% *Sirt6* mRNA levels higher than VP64-WT) and A2+CA10.11 (20% *Nrf2* mRNA levels higher than VP64-WT) exerted stronger activation effects than the original CRISPRa (Figure 5). However, the degree of activation is gene-dependent.

### Figure 3. VP64 variants identification. Amino acid alignments of wild-type and mutant VP64

Blue highlighted red letters indicate the substitution mutations on VP64 sequence, while red dashed lines indicate the deleted sequences on VP64. Green highlighted amino acids indicate four copies of VP16 in wild-type VP64, while yellow highlighted green letters represent the most critical amino acid (Phe<sup>442</sup>) in VP16. The full length of VP64 transgene is 165 base pairs (55 amino acids).



### AAV delivery of ΔCRISPRa for targeted endogenous gene activation *in vitro*

Given the promising activation effects on two endogenous genes observed for ΔCRISPRa bearing CA10.11-, A2-, or S4-VP64, we packaged these ΔCRISPRa transgenes into the AAV1-PHP.B vector (Figure 6A). AAV1-PHP.B is a capsid-modified AAV serotype 1 (AAV1) that provided higher transduction efficiency than the wild-type AAV1 (Figure 6B). Similar to the results of plasmid transfection, through AAV delivery, these three ΔCRISPRa particularly the one bearing CA10.11-VP64 exerted stronger activation effects (20% *Sirt6* mRNA level higher than the VP64-WT) to *SIRT6* promoter than the original CRISPRa (Figure 6C).

### DISCUSSION

Here, we have successfully enhanced VP64 activation potency and improved overall CRISPRa function through PAM-flexible dual base editor-mediated genetic diversification of the VP64 at a genomic safe harbor, followed by self-activation of modified CRISPRa in the living cells. This integrated approach used CRISPR-SpCas9-mediated homologous recombination and CRISPR-dSpCas9-mediated base editing to derive CRISPR-dSaCas9 activator with an enhanced function. The PAM sequence requirements for dSpCas9 of base editor and dSaCas9 of CRISPRa are different, thereby avoiding competition between base editor and CRISPRa for sgRNA in the cell. The PAM-flexible dual base editor-mediated mutagenesis and self-activation strategies described here allow positive selection of GFP-expressing cells with the desired VP64 mutants for culturing and expanding.

We generated diverse VP64 mutants in the living cells by mutagenesis of the VP64 transgene using different CRISPR base editors with multiple sgRNAs. Compared with the structure-based rational design, our base editor-mediated mutagenesis and self-activation strategies allow selection of novel variants having greater enhancement effect without relying on protein structural and evolutionary features. Notably, our integrated approach enables feasible selection of the most promising traits from a large number of variants upon mutagenesis, thereby minimizing complexity and improving feasibility in high-throughput screening. Base editor is preferable to nuclease-based editing tools because it enables direct nucleotide substitutions without damaging the target DNA or requiring donor



**Figure 4. Functionality screening of VP64 variants**

(A) Identification of the most potent sgRNA target site on TK promoter for constructing CMV-dSaCas9-ΔVP64. A 750-base pair TK promoter was cloned at the upstream of the chimeric intron and Renilla luciferase gene (Rluc). Arrows indicate the sense or antisense orientation of sgRNAs designed to recognize target DNA sequences. (B) Renilla luciferase activity with CRISPRa bearing different VP64 mutants. pAAV-CMV-dSaCas9-ΔVP64 (CRISPRa) transgene targeting the TK promoter was co-transfected with pTK-Rluc vector into HEK293FT cells. Two independent experiments with four replicates were carried out. The statistical significance levels from VP64-WT are indicated as \* $p < 0.05$ , \*\* $p < 0.01$ , and \*\*\* $p < 0.001$ . All data are presented as mean  $\pm$  SD. ITR, inverted terminal repeats; NLS, nuclear localization signal; pTK, thymidine kinase promoter; Rluc, Renilla luciferase.


cific hydrophobic interactions contribute to VP16 function. However, bulky hydrophobic residues, not acidic residues, are the most critical for VP16 activation activity.<sup>39</sup> Multimerized VP16 activation domains could induce transcription synergistically in mammalian cells by increasing the stability of the transcription complex formation.<sup>37</sup>

The structural elements critical for VP16 function have been extensively studied.<sup>40–43</sup> A phenylalanine residue at position 442 of VP16 was exquisitely sensitive to substitution mutation, thus Phe<sup>442</sup> is very critical for VP16 activation activity.<sup>40,42</sup> Phe<sup>442</sup> of VP16 makes a critical hydrophobic contact with transcription factor II D (TFIID) that makes up the RNA polymerase II preinitiation complex. It is also important for the structure of the VP16 activation domain. The substitution with the nonaromatic residues at Phe<sup>442</sup> could completely abolish transcriptional activation by VP16. In fact, in our luciferase screening, none of the VP64 variant with mutation at this residue displayed higher activation activity than the wild-type VP64.

In our study, the substitution mutations of CA10.11 (Asp443Asn and Asp437His of VP16) and A2 (Asp445Asn of VP16) of VP64 were located in the vicinity of Phe<sup>442</sup>. For Asp443Asn and Asp445Asn, the acidic charge of aspartic acid (Asp) was replaced with the uncharged -NH<sup>2</sup> group of asparagine (Asn). A previous study has shown that asparagine substitution to the aspartate residues proximal to the Phe<sup>442</sup> conserved most of the VP16 activation activity, while glutamate and alanine were poor substitutes for aspartate.<sup>40</sup> Although a subsequent study revealed aromatic amino acids such as tyrosine and tryptophan are the best substitutes for Phe<sup>442</sup>, the effects of Asp443Asn and Asp445Asn substitutions on VP16 activation activity have not been

DNA.<sup>22,23,25,36</sup> Therefore, it will not cause reading frameshift that can lead to the generation of truncated, non-functional VP64. Base editor also is more efficient than homology-directed oligonucleotide integration approaches.<sup>22,25</sup> Base editor also has a broad editing window (4–5 nucleotides), thereby enabling introduction of diverse substitution mutations to the VP64.<sup>22,25</sup> Therefore, base editor can create a diverse repertoire of point mutations *in situ* without the need to use error-prone PCR to create mutations *in vitro* or design a large number of DNA oligos for incorporating into a genomic locus.<sup>22,25</sup>

We have identified several VP64 variants, particularly CA10.11 and A2 that are more potent than the wild-type VP64. VP64 bears four VP16 core transactivation domains.<sup>37</sup> Virion protein 16 (VP16) of herpes simplex virus type 1 was identified as a potent acidic transcriptional activator of the viral immediate-early genes.<sup>38</sup> Both ionic and structure-spe-



**Figure 5. Activation of endogenous genes in HEK293FT cells by evolved CRISPRa**

Targeted activation of endogenous human (A) *KLOTHO*, (B) *SIRT6*, and (C) *NFE2L2* genes. Red arrows indicate the sense or antisense orientation of sgRNAs designed to recognize target DNA sequences on the promoter. Bottom panel shows the relative expression level of endogenous genes in HEK293FT cells. The statistical significance levels from VP64-WT are indicated as \* $p < 0.05$ , \*\* $p < 0.01$ , and \*\*\* $p < 0.001$ . All data are presented as mean  $\pm$  SD ( $n = 3$ ).

Although our  $\Delta$ CRISPRa is more potent than the original CRISPRa, it exerted a modest activation to the target endogenous genes in the presence of one sgRNA. To derive more potent AAV-compatible CRISPRa, smaller Cas proteins (e.g., CRISPR-CasPhi<sup>45</sup>) or truncated small dCas9 orthologues (e.g., mini-dSaCas9<sup>46</sup>) can be used alongside with other larger effector domains. Apart from small VP64 transactivation domain, mutagenesis of a large dSaCas9 can give more possibility to greatly improve CRISPRa potency and minimize the overall size of CRISPRa for efficient AAV packaging. To further reduce the payload size, truncated effector domains such as truncated VPR transactivation domain can be used.<sup>46,47</sup> For example, a recent study has successfully packaged a compact and robust miniCas9 activator (dCjCas9-VPR) into an all-in-one AAV vector for *in vivo* target gene activation.<sup>48</sup> Alternatively, to enable synergistic transcription activation with a single AAV vector platform, self-cleaving ribozyme or tRNA can be used to replace U6 promoter for driving multiple sgRNA expressions.<sup>49</sup>

Instead of using AAV1-PHP.B vector, the use of AAV-PHP.eB<sup>50</sup> or AAV.CAP-B10<sup>51</sup> could further improve  $\Delta$ CRISPRa performance, particularly in neuronal cells by maximizing the cellular transduction efficiency. AAV-PHP.eB is an enhanced variant of AAV-PHP.B, which provides higher blood-brain-barrier crossing ability and transduction efficiency of neurons throughout the adult mouse brain.<sup>50</sup> Therefore, it can lower the systemic dose and viral load required to transduce the central nervous system. AAV-PHP.eB (DGTLAVPFK) was evolved from the AAV-PHP.B (TLAVPFK) by screening an AAV9-based 7-mer library in GFAP-Cre mice. On the other hand, AAV.CAP-B10 was further evolved from AAV-PHP.eB to provide higher specificity for neurons in the central nervous system, while decreasing liver targeting.<sup>51</sup>


## MATERIALS AND METHODS

### Cell line cultures

Human HEK293FT cells were cultured in Dulbecco's modified Eagle's medium (high glucose) (Gibco 11,965,092) with 10% fetal bovine

explored.<sup>43</sup> In the case of VP64, asparagine substitution to the aspartate residues close to Phe<sup>442</sup> of VP16 enhanced VP64 transcription activation potency, probably by affecting VP64 folding, the physical contact of the molecular target of VP64, or transcriptional synergism in multimerized VP16 activation domains. To support this notion, mutated at Phe<sup>442</sup> alone was shown insufficient to affect transcriptional synergism of VP16, and other residues in the vicinity of Phe<sup>442</sup> are more important for synergistic effects of VP16.<sup>44</sup>

Compared with Asp443Asn and Asp445Asn, Asp437His is located slightly farther away from the Phe<sup>442</sup> residue. Therefore, substitution of basic charged histidine to the aspartate residue in CA10.11 VP64 may not affect VP64 function as much as Asp443Asn. Moreover, net negative charge is not the sole determinant of VP16 activation activity, but also the domain structure and surface interactions with target proteins.<sup>43</sup>



**Figure 6. AAV delivery of an evolved CRISPRa for targeted gene activation in HEK293FT cells**

(A) Packaging of CRISPRa (CMV-dSaCas9-ΔVP64) by AAV1-WT and AAV1-PHP.B. AAV1-PHP.B was generated by inserting a 7-mer PHP.B peptide sequence in between S588 and T589 of the AAV1 capsid. (B) Transduction efficiency of AAV1-WT and AAV1-PHP.B in HEK293FT cells. Flow cytometry analysis and GFP fluorescent images were taken 3 days after the AAV transduction. (C) qPCR of *SIRT6* expressions upon targeted activation of this endogenous gene by AAV delivery of CRISPRa. Red arrows indicate the antisense orientation of sgRNAs designed to recognize target DNA sequences on the promoter. The statistical significance levels from VP64-WT are indicated as \* $p < 0.05$ . All data are presented as mean  $\pm$  SD ( $n = 3$ ).

pTK-dSaCas9-VP64-2A-GFP-pU6-sgRNA using XhoI and XbaI. Finally, the right AAVS1 homology arm was inserted using NotI. The left and right AAVS1 homology arms were amplified from genomic DNA of HEK293FT cells. This donor transgene pTK-dSaCas9-VP64-2A-GFP-pU6-sgRNA harboring two flanking AAVS1 homology arms is abbreviated as pTK-CRISPRa-GFP. Primers used for vector construction are listed in Table S1.

#### Generation of a HEK293FT transgenic clone stably expressing pTK-CRISPRa-GFP

At 1 day prior to plasmid transfection,  $1 \times 10^5$  HEK293FT cells were seeded into each well of a 6-well plate. Briefly, 1,250 ng of donor pTK-CRISPRa-GFP and 1,250 ng of CRISPR-Cas9 (Addgene 42,230) targeting the *AAVS1* site were mixed with 5  $\mu$ L of P3000 Reagent and 7.5  $\mu$ L of Lipofectamine 3000 (Invitrogen) in 1 mL of Opti-MEM I Reduced Serum Medium (Gibco). The transfection mixture was added to the cells and incubated overnight. After 7 days, GFP-positive cells were single-cell sorted and expanded on a 96-well plate. The genomic DNA of these clones was then extracted for PCR genotyping. Primers used for *AAVS1*-directed knockin are listed in Table S2.

serum (Gibco 10,270,106). The cells were cultured under a standard cell culture condition (37°C, 5% CO<sub>2</sub>) in a humidified incubator.

#### Donor vector construction (pTK-dSaCas9-VP64-2A-GFP-pU6-sgRNA)

First, we inserted a 22-bp guide sequence targeting TK promoter to the sgRNA of our previously constructed pMecp2-dSaCas9-VP64-pU6-sgRNA<sup>6</sup> using BsaI. Next, we constructed pMecp2-dSaCas9-VP64-2A-GFP-pU6-sgRNA by replacing VP64 of pMecp2-dSaCas9-VP64-pU6-sgRNA with VP64-2A-GFP using BamHI and EcoRI. The VP64-2A-GFP was amplified from dCAS9-VP64-GFP vector (Addgene 61,422). Then, we replaced pMecp2 with pTK to construct pTK-dSaCas9-VP64-2A-GFP-pU6-sgRNA using XbaI and AgeI. The pTK was amplified from pRL-TK vector (Promega E2241). Then, we inserted a left AAVS1 homology arm to this

#### VP64 mutagenesis in the HEK293FT clone expressing pTK-CRISPRa-GFP

The dCas9-based base editors, including ABE7.10<sup>22</sup> (Addgene 102,919), BE3<sup>22</sup> (Addgene 73,021), ABEmax<sup>23</sup> (Addgene 112,095), AncBE4max<sup>23</sup> (Addgene 112,094), BE4max<sup>23</sup> (Addgene 112,093), and AID(P182X)<sup>24</sup> (Addgene 83,260) were used for mutagenesis of VP64 transgene in the HEK293FT C2.8 clone expressing pTK-CRISPRa-GFP. Using these dCas9-based base editors, only four sgRNAs (Addgene 53,188) of base editor could be designed to target four different sites on the VP64 transgene. To maximize the number of VP64 variants generated, we also used PAM-flexible (SpRY<sup>19</sup> and



nCas9-NG<sup>20</sup>) (Addgene 139,999, 140,003) and dual base editors (A&C-BE<sub>max</sub>-nCas9<sup>21</sup> and TadA-nCas9-NG-CDA1<sup>20</sup>) (Addgene 140,244, 157,947) for VP64 mutagenesis. At 1 day prior to plasmid transfection,  $1 \times 10^5$  of HEK293FT cells expressing pTK-CRISPRa-GFP were seeded into each well of a 24-well plate. Briefly, 250 ng of base editors and 250 ng of sgRNAs were mixed with 1  $\mu$ L of P3000 Reagent and 1.5  $\mu$ L of Lipofectamine 3000 (Invitrogen) in 200  $\mu$ L of Opti-MEM I Reduced Serum Medium (Gibco). For co-transfection of multiple base editors or multiple sgRNAs, an equal amount of each plasmid vector was added. After 7 days, the brightest GFP-expressing cells were single-cell sorted and expanded on a 96-well plate. The clones with the GFP fluorescence intensity stronger than the original transgenic cell (before VP64 mutagenesis) were selected for genomic DNA extraction. PCR was then carried out to amplify the full-length VP64 sequence for DNA sequencing. Primers used for VP64 mutagenesis experiments are listed in Table S3.

#### Construction of CRISPRa variants (pAAV-CMV-dSaCas9- $\Delta$ VP64)

First, we replaced pMecp2 with pCMV to our previously constructed pAAV-pMecp2-dSaCas9-VP64(WT)-pU6-sgRNA using XbaI and AgeI. The pCMV was amplified from SP-dCas9-VPR vector (Addgene 63,798). Next, we replaced wild-type VP64 with mutated VP64 ( $\Delta$ VP64) using BamHI and EcoRI. The  $\Delta$ VP64 sequences were amplified from the genomic DNA of HEK293FT clones expressing pTK-CRISPRa-GFP-pU6-sgRNA. For construction of  $\Delta$ CRISPRa bearing both  $\Delta$ VP64 A2 and CA10.11, duplexed ultramer DNA oligonucleotides (IDT) consisting of the full-length VP64 sequence bearing these two mutations were custom synthesized. The successful  $\Delta$ VP64 A2+CA10.11 replacement to  $\Delta$ CRISPRa was verified using SphI and HindIII. Primers used for construction of CRISPRa variants and their guide sequences are listed in Tables S4 and S5.

#### Design of CRISPR guide sequences

To construct the guide sequence, a pair of annealed oligos was cloned into the sgRNA of CRISPR-Cas9 and base editors using BbsI. A guide sequence was cloned into the sgRNA of CRISPRa using BsaI. The CRISPR RGEN Tool, Cas-Designer (<http://www.rgenome.net/cas-designer/>), was used to identify the target sequence of sgRNAs. The first nucleotide of the transcribed gRNA was a guanine nucleotide (G) to maximize U6 promoter activity. For CRISPRa, BsaI and HindIII were used to screen the clones with target sequence insertion. Then the pU6-seq primer was used for DNA sequencing to confirm successful guide sequence insertion in the sgRNA.

#### Luciferase bioluminescence reporter assays

At 1 day prior to plasmid transfection,  $1 \times 10^4$  HEK293FT cells were seeded into each well of a 96-well plate. Using Lipofectamine 3000 Transfection Reagent (Invitrogen), the pRL-TK (Promega E2241) (50 ng/well) and pAAV-CMV-dSaCas9- $\Delta$ VP64 (50 ng/well) plasmid vectors were co-transfected at a ratio of 1:1 into the 96-well plate. After 48 h of transfection, cells were lysed and quantified for the luciferase activity using the Renilla Luciferase Assay System (Promega E2810). The Renilla luminescence on a 96-well white polystyrene

plate was measured with the SpectraMax M5e Microplate Reader (Molecular Devices). Two independent experiments with four replicates for each experimental group were performed.

#### Plasmid transfection of CRISPRa

At 1 day prior to plasmid transfection,  $1 \times 10^5$  HEK293FT cells were seeded into each well of a 24-well plate. Briefly, 500 ng of pAAV-CMV-dSaCas9- $\Delta$ VP64 targeting *KLOTHO* or *SIRT6* or *NFE2L2* were mixed with 1  $\mu$ L of P3000 Reagent and 1.5  $\mu$ L of Lipofectamine 3000 (Invitrogen) in 200  $\mu$ L of Opti-MEM I Reduced Serum Medium (Gibco). The transfection mixture was added to the cells and incubated overnight. After 2 days of plasmid transfection, cells were harvested for total RNA extraction.

#### Recombinant AAV vector production and titrating

At 1 day before plasmid transfection,  $\sim 7 \times 10^6$  HEK293FT cells were seeded on each 100-mm dish. To generate recombinant AAV vectors, HEK293FT cells were transfected with transgene plasmid (pAAV-CMV-dSaCas9- $\Delta$ VP64 or pAAV-CMV-GFP), pAAV1 serotype vector (AAV1-WT or AAV1-PHP.B), and pHelper vector at a 1:1:1 ratio using Calcium Phosphate Transfection Kit (Invitrogen K278001), with some modifications. Briefly, 4 h prior to transfection, the culture media in each 100-mm dish were replaced with 12 mL of fresh media consisting of 1% heat-inactivated fetal bovine serum (Gibco 10,082,139). Then, 600  $\mu$ L of transfection mixture that consisted of 36  $\mu$ L of 2M CaCl<sub>2</sub>, 20  $\mu$ g of DNA, 300  $\mu$ L of 2x HEPES-buffered saline, and H<sub>2</sub>O was added to the cells. After 72 h of plasmid transfection, culture media from each 100-mm dish were collected into a 15-mL tube for AAV particle extraction. AAV particles from media were extracted using AAVanced Concentration Reagent (SBI AAV100A-1). Briefly, one volume of cold AAVanced Concentration Reagent was added to four volumes of AAV particle-containing media. The mixture was then incubated at 4°C in the refrigerator overnight. The next day, the mixture was spun at 1500 x g for 30 min, followed by pellet washing once and spinning again for 3 min. Finally, the pellet was resuspended in 50  $\mu$ L using cold PBS. The concentrated virus was aliquoted for storing in -80°C freezer. Viral genomes were extracted and titered using TaqMan qPCR according to our recent published paper (Table S6).<sup>6</sup>

#### AAV transduction of CRISPRa

At 1 day prior to AAV transduction,  $1 \times 10^5$  HEK293FT cells were seeded into each well of a 24-well plate. On the next day, the culture media in each well were replaced with 250  $\mu$ L of 1% heat-inactivated fetal bovine serum (FBS) media. After 4 h of media replacement, AAV particles were added directly to the cells. After 24 h of AAV infection, the transduction mixture was removed and the cells were maintained in 1 mL of fresh culture media containing 1% heat-inactivated FBS (Gibco). For transductions of AAV-CMV-dSaCas9- $\Delta$ VP64, AAV particles were added at an MOI of 30,000 viral genomes/cell. After 3 days of AAV infection, cells transduced with AAV-CMV-dSaCas9- $\Delta$ VP64 were harvested for total RNA extraction. For cells transduced with AAV-CMV-GFP, GFP-expressing individual cells

were analyzed with flow cytometry and imaged with fluorescent microscopy.

#### qPCR and melt curve analysis

Total RNA was extracted from the HEK293FT cells with the RNeasy Mini Kit (QIAGEN 74104) and treated with DNase I to digest genomic DNA (QIAGEN 79254). The concentration and purity of total RNAs were then determined with a Biochrom spectrophotometer. The total harvested RNA was reverse transcribed using SuperScript III First-Strand Synthesis System (Invitrogen 18,080,051), according to the manufacturer's protocol.

For qPCR, the SsoAdvanced Universal SYBR Green Supermix (Bio-Rad 1,725,271) was used to amplify the synthesized cDNA. The mixture for each qPCR reaction was 10  $\mu$ L of 2X SsoAdvanced Universal SYBR Green Supermix, 0.2  $\mu$ L of 10  $\mu$ M forward primer, 0.2  $\mu$ L of 10  $\mu$ M reverse primer, 2  $\mu$ L of 2.5 ng/ $\mu$ L cDNA sample, and 7.6  $\mu$ L of nuclease-free water. qPCR was done by using Thermal Cycling (Bio-Rad CFX96 Connect System). qPCR was carried out as follows: an initial denaturation step at 95°C for 3 min followed by 40 cycles at 95°C for 15 s and 55°C for 45 s (for *Klortho* mRNA), 58°C for 45 s (for *Sirt6* mRNA), or 60°C for 45 s (for *Nrf2* mRNA). The housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (*Gapdh*) was used for internal normalization. Relative quantification of gene expression was calculated using the 2- $\Delta\Delta$ Ct method. Technical triplicates for each sample were performed. Melt curve analysis was done at 65°C–95°C with 0.5°C increments and 2 to 5 s/step to check specificity of the primers and to ensure no primer-dimer formation during the qPCR. An exon-exon junction primer was designed to avoid genomic DNA amplification during the qPCR. Primers used for qRT-PCR are listed in Table S7.

#### Cell sorting and flow cytometry analysis

BD FACSMelody cell sorter (BD Biosciences) was used to sort GFP-expressing cells, while BD FACSVerser flow cytometer (BD Biosciences) was used to analyze GFP-expressing cells. The fluorescent channel fluorescein isothiocyanate (FITC) was used to detect the GFP-expressing cells; 100,000 cells were analyzed for each sample.

#### Statistical analysis

Using the Minitab Express Program, significant differences in continuous variables among subject groups were confirmed by ANOVA, followed by Dunnett post hoc multiple comparisons. All p values were two tailed. The statistical significance levels are indicated as \*p < 0.05, \*\*p < 0.01, and \*\*\*p < 0.001. All data are presented as mean  $\pm$  SD.

#### Conclusions

We have successfully utilized PAM-flexible dual base editor-mediated mutagenesis and self-activation strategies to derive VP64 variants with gain-of-function mutations. Importantly, these VP64 variants could improve the potency of an all-in-one CRISPRa for application of a single AAV vector platform. However, multiple sgRNAs are still needed for robust target gene activation due to the modest improve-

ment of the function of our current  $\Delta$ CRISPRa. This mutagenesis study not only provided insights into the structural elements critical for VP64 function, it also represents a proof of concept for evolving CRISPR activators through integration use of different CRISPR variants and approaches.

#### Data availability statement

All data and supporting materials are available within the article and supplemental information.

#### SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.omtm.2022.04.014>.

#### ACKNOWLEDGMENTS

This work was supported by the Research Grants Council of the Hong Kong Special Administrative Region [grant number CityU11213717, CityU11104220 and CityU11215619] and City University of Hong Kong [grant number CityU7005088].

#### AUTHOR CONTRIBUTIONS

C.T. conceived and supervised the project. C.H.L. and S.H. designed and performed the experiments. C.H.L. and S.H. collected and analyzed the data. C.H.L., S.H., R.H.W.L., and C.T. discussed the results, and wrote and revised the manuscript. All authors read, corrected, and approved the final manuscript.

#### DECLARATION OF INTERESTS

The authors declare no competing interests.

#### REFERENCES

- Lau, C.H. (2018). Applications of CRISPR-Cas in bioengineering, biotechnology, and translational research. *CRISPR J* 1, 379–404. <https://doi.org/10.1089/crispr.2018.0026>.
- Kampmann, M. (2018). CRISPRi and CRISPRa screens in mammalian cells for precision biology and medicine. *ACS Chem. Biol.* 13, 406–416. <https://doi.org/10.1021/acscmbio.7b00657>.
- La Russa, M.F., and Qi, L.S. (2015). The new state of the art: Cas9 for gene activation and repression. *Mol. Cell. Biol.* 35, 3800–3809. <https://doi.org/10.1128/mcb.00512-15>.
- Grimm, D., and Büning, H. (2017). Small but increasingly mighty: latest advances in AAV vector research, design, and evolution. *Hum. Gene. Ther.* 28, 1075–1086. <https://doi.org/10.1089/hum.2017.172>.
- Lau, C.H., and Suh, Y. (2017). In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease. *F1000Res* 6, 2153. <https://doi.org/10.12688/f1000research.11243.1>.
- Lau, C.H., Ho, J.W.T., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. *Mol. Ther. Nucleic Acids* 16, 637–649. <https://doi.org/10.1016/j.omtn.2019.04.015>.
- Ran, F.A., Cong, L., Yan, W.X., Scott, D.A., Gootenberg, J.S., Kriz, A.J., Zetsche, B., Shalem, O., Wu, X., Makarova, K.S., et al. (2015). In vivo genome editing using Staphylococcus aureus Cas9. *Nature* 520, 186–191. <https://doi.org/10.1038/nature14299>.
- Maeder, M.L., Linder, S.J., Cascio, V.M., Fu, Y., Ho, Q.H., and Joung, J.K. (2013). CRISPR RNA-guided activation of endogenous human genes. *Nat. Methods* 10, 977–979. <https://doi.org/10.1038/nmeth.2598>.
- Gilbert, L.A., Horlbeck, M.A., Adamson, B., Villalta, J.E., Chen, Y., Whitehead, E.H., Guimaraes, C., Panning, B., Ploegh, H.L., Bassik, M.C., et al. (2014). Genome-scale

- CRISPR-mediated control of gene repression and activation. *Cell* 159, 647–661. <https://doi.org/10.1016/j.cell.2014.09.029>.
10. Perez-Pinera, P., Kocak, D.D., Vockley, C.M., Adler, A.F., Kabadi, A.M., Polstein, L.R., Thakore, P.I., Glass, K.A., Ousterout, D.G., Leong, K.W., et al. (2013). RNA-guided gene activation by CRISPR-Cas9-based transcription factors. *Nat. Methods* 10, 973–976. <https://doi.org/10.1038/nmeth.2600>.
  11. Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. *Nat. Biotechnol.* 34, 204–209. <https://doi.org/10.1038/nbt.3440>.
  12. Galvan, A., Petkau, T.L., Hill, A.M., Korecki, A.J., Lu, G., Choi, D., Rahman, K., Simpson, E.M., Leavitt, B.R., and Smith, Y. (2021). Intracerebroventricular administration of AAV9-PHP.B SYN1-EmGFP induces widespread transgene expression in the mouse and monkey central nervous system. *Hum. Gene Ther.* 32, 599–615. <https://doi.org/10.1089/hum.2020.301>.
  13. Silva-Pinheiro, P., Cerutti, R., Luna-Sanchez, M., Zeviani, M., and Viscomi, C. (2020). A single intravenous injection of AAV-PHP.B-hNDUFS4 ameliorates the phenotype of *Ndufs4* (-/-) Mice. *Mol Ther Methods Clin Dev* 17, 1071–1078. <https://doi.org/10.1016/j.omtm.2020.04.026>.
  14. Lim, J.A., Yi, H., Gao, F., Raben, N., Kishnani, P.S., and Sun, B. (2019). Intravenous injection of an AAV-PHP.B vector encoding human acid alpha-glucosidase rescues both muscle and CNS defects in murine pompe disease. *Mol Ther Methods Clin Dev* 12, 233–245. <https://doi.org/10.1016/j.omtm.2019.01.006>.
  15. Chavez, A., Scheiman, J., Vora, S., Pruitt, B.W., Tuttle, M., P R Iyer, E., Lin, S., Kiani, S., Guzman, C.D., Wiegand, D.J., et al. (2015). Highly efficient Cas9-mediated transcriptional programming. *Nat. Methods* 12, 326–328. <https://doi.org/10.1038/nmeth.3312>.
  16. Liu, X.S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., Shu, J., Dadon, D., Young, R.A., and Jaenisch, R. (2016). Editing DNA methylation in the mammalian genome. *Cell* 167, 233–247.e17. <https://doi.org/10.1016/j.cell.2016.08.056>.
  17. Hilton, I.B., D'Ippolito, A.M., Vockley, C.M., Thakore, P.I., Crawford, G.E., Reddy, T.E., and Gersbach, C.A. (2015). Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. *Nat. Biotechnol.* 33, 510–517. <https://doi.org/10.1038/nbt.3199>.
  18. Cano-Rodriguez, D., Gjaltema, R.A.F., Jilderda, L.J., Jellema, P., Dokter-Fokkens, J., Ruiters, M.H.J., and Rots, M.G. (2016). Writing of H3K4Me3 overcomes epigenetic silencing in a sustained but context-dependent manner. *Nat. Commun.* 7, 12284. <https://doi.org/10.1038/ncomms12284>.
  19. Walton, R.T., Christie, K.A., Whittaker, M.N., and Kleinstiver, B.P. (2020). Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. *Science* 368, 290–296. <https://doi.org/10.1126/science.aba8853>.
  20. Grünewald, J., Zhou, R., Lareau, C.A., Garcia, S.P., Iyer, S., Miller, B.R., Langner, L.M., Hsu, J.Y., Aryee, M.J., and Joung, J.K. (2020). A dual-deaminase CRISPR base editor enables concurrent adenine and cytosine editing. *Nat. Biotechnol.* 38, 861–864. <https://doi.org/10.1038/s41587-020-0535-y>.
  21. Zhang, X., Zhu, B., Chen, L., Xie, L., Yu, W., Wang, Y., Li, L., Yin, S., Yang, L., Hu, H., et al. (2020). Dual base editor catalyzes both cytosine and adenine base conversions in human cells. *Nat. Biotechnol.* 38, 856–860. <https://doi.org/10.1038/s41587-020-0527-y>.
  22. Komor, A.C., Kim, Y.B., Packer, M.S., Zuris, J.A., and Liu, D.R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* 533, 420–424. <https://doi.org/10.1038/nature17946>.
  23. Koblan, L.W., Doman, J.L., Wilson, C., Levy, J.M., Tay, T., Newby, G.A., Maianti, J.P., Raguram, A., and Liu, D.R. (2018). Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. *Nat. Biotechnol.* 36, 843–846. <https://doi.org/10.1038/nbt.4172>.
  24. Ma, Y., Zhang, J., Yin, W., Zhang, Z., Song, Y., and Chang, X. (2016). Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells. *Nat. Methods* 13, 1029–1035. <https://doi.org/10.1038/nmeth.4027>.
  25. Gaudelli, N.M., Komor, A.C., Rees, H.A., Packer, M.S., Badran, A.H., Bryson, D.I., and Liu, D.R. (2017). Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. *Nature* 551, 464–471. <https://doi.org/10.1038/nature24644>.
  26. Chen, C.D., Zeldich, E., Li, Y., Yuste, A., and Abraham, C.R. (2018). Activation of the anti-aging and cognition-enhancing gene *Klotho* by CRISPR-dCas9 transcriptional effector complex. *J. Mol. Neurosci.* 64, 175–184. <https://doi.org/10.1007/s12031-017-1011-0>.
  27. Kurosu, H., Yamamoto, M., Clark, J.D., Pastor, J.V., Nandi, A., Gurnani, P., McGuinness, O.P., Chikuda, H., Yamaguchi, M., Kawaguchi, H., et al. (2005). Suppression of aging in mice by the hormone *Klotho*. *Science* 309, 1829–1833. <https://doi.org/10.1126/science.1112766>.
  28. Yamamoto, M., Clark, J.D., Pastor, J.V., Gurnani, P., Nandi, A., Kurosu, H., Miyoshi, M., Ogawa, Y., Castrillon, D.H., Rosenblatt, K.P., and Kuro-o, M. (2005). Regulation of oxidative stress by the anti-aging hormone *klotho*. *J. Biol. Chem.* 280, 38029–38034. <https://doi.org/10.1074/jbc.m509039200>.
  29. Mostoslavsky, R., Chua, K.F., Lombard, D.B., Pang, W.W., Fischer, M.R., Gellon, L., Liu, P., Mostoslavsky, G., Franco, S., Murphy, M.M., et al. (2006). Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. *Cell* 124, 315–329. <https://doi.org/10.1016/j.cell.2005.11.044>.
  30. Michishita, E., McCord, R.A., Berber, E., Kioi, M., Padilla-Nash, H., Damian, M., Cheung, P., Kusumoto, R., Kawahara, T.L.A., Barrett, J.C., et al. (2008). SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. *Nature* 452, 492–496. <https://doi.org/10.1038/nature06736>.
  31. Peshti, V., Obolensky, A., Nahum, L., Kanfi, Y., Rathaus, M., Avraham, M., Tinman, S., Alt, F.W., Banin, E., and Cohen, H.Y. (2017). Characterization of physiological defects in adult SIRT6<sup>-/-</sup> mice. *PLoS. One.* 12, e0176371. <https://doi.org/10.1371/journal.pone.0176371>.
  32. Kanfi, Y., Naiman, S., Amir, G., Peshti, V., Zinman, G., Nahum, L., Bar-Joseph, Z., and Cohen, H.Y. (2012). The sirtuin SIRT6 regulates lifespan in male mice. *Nature* 483, 218–221. <https://doi.org/10.1038/nature10815>.
  33. Nguyen, T., Nioi, P., and Pickett, C.B. (2009). The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. *J. Biol. Chem.* 284, 13291–13295. <https://doi.org/10.1074/jbc.r900012020>.
  34. Gazaryan, I.G., and Thomas, B. (2016). The status of Nrf2-based therapeutics: current perspectives and future prospects. *Neural. Regen. Res.* 11, 1708. <https://doi.org/10.4103/1673-5374.194706>.
  35. Al-Sawaf, O., Clarner, T., Fragoulis, A., Kan, Y.W., Pufe, T., Streetz, K., and Wruck, C.J. (2015). Nrf2 in health and disease: current and future clinical implications. *Clin. Sci. (Lond.)* 129, 989–999. <https://doi.org/10.1042/cs20150436>.
  36. Liu, X., Li, G., Zhou, X., Qiao, Y., Wang, R., Tang, S., Liu, J., Wang, L., and Huang, X. (2019). Improving editing efficiency for the sequences with NGH PAM using xCas9-derived base editors. *Mol. Ther. Nucleic Acids* 17, 626–635. <https://doi.org/10.1016/j.omtn.2019.06.024>.
  37. Emami, K.H., and Carey, M. (1992). A synergistic increase in potency of a multimerized VP16 transcriptional activation domain. *EMBO. J.* 11, 5005–5012. <https://doi.org/10.1002/j.1460-2075.1992.tb05607.x>.
  38. Sadowski, I., Ma, J., Triezenberg, S., and Ptashne, M. (1988). GAL4-VP16 is an unusually potent transcriptional activator. *Nature* 335, 563–564. <https://doi.org/10.1038/335563a0>.
  39. Sullivan, S.M., Horn, P.J., Olson, V.A., Koop, A.H., Niu, W., Ebright, R.H., and Triezenberg, S.J. (1998). Mutational analysis of a transcriptional activation region of the VP16 protein of herpes simplex virus [published erratum appears in *Nucleic Acids Res* 1998 Dec 1;26(23):537-8]. *Nucleic. Acids. Res.* 26, 4487–4496. <https://doi.org/10.1093/nar/26.19.4487>.
  40. Cress, W.D., and Triezenberg, S.J. (1991). Critical structural elements of the VP16 transcriptional activation domain. *Science* 251, 87–90. <https://doi.org/10.1126/science.1846049>.
  41. Berger, S.L., Cress, W.D., Cress, A., Triezenberg, S.J., and Guarente, L. (1990). Selective inhibition of activated but not basal transcription by the acidic activation domain of VP16: evidence for transcriptional adaptors. *Cell* 61, 1199–1208. [https://doi.org/10.1016/0092-8674\(90\)90684-7](https://doi.org/10.1016/0092-8674(90)90684-7).
  42. Ingles, C.J., Shales, M., Cress, W.D., Triezenberg, S.J., and Greenblatt, J. (1991). Reduced binding of TFIID to transcriptionally compromised mutants of VP16. *Nature* 351, 588–590. <https://doi.org/10.1038/351588a0>.
  43. Regier, J.L., Shen, F., and Triezenberg, S.J. (1993). Pattern of aromatic and hydrophobic amino acids critical for one of two subdomains of the VP16 transcriptional activator. *Proc. Natl. Acad. Sci. U S A* 90, 883–887. <https://doi.org/10.1073/pnas.90.3.883>.


44. Ghosh, S., Toth, C., Peterlin, B.M., and Seto, E. (1996). Synergistic activation of transcription by the mutant and wild-type minimal transcriptional activation domain of VP16. *J. Biol. Chem.* *271*, 9911–9918. <https://doi.org/10.1074/jbc.271.17.9911>.
45. Pausch, P., Al-Shayeb, B., Bisom-Rapp, E., Tsuchida, C.A., Li, Z., Cress, B.F., Knott, G.J., Jacobsen, S.E., Banfield, J.F., and Doudna, J.A. (2020). CRISPR-Cas $\Phi$  from huge phages is a hypercompact genome editor. *Science* *369*, 333–337. <https://doi.org/10.1126/science.abb1400>.
46. Ma, D., Peng, S., Huang, W., Cai, Z., and Xie, Z. (2018). Rational design of mini-Cas9 for transcriptional activation. *ACS Synth. Biol.* *7*, 978–985. <https://doi.org/10.1021/acssynbio.7b00404>.
47. Vora, S., Cheng, J., Xiao, R., VanDusen, N., Quintino, L., Pu, W., Vandenberghe, L., Chavez, A., and Church, G. (2018). Rational design of a compact CRISPR-Cas9 activator for AAV-mediated delivery. Preprint at bioRxiv. <https://doi.org/10.1101/298620>.
48. Zhang, X., Lv, S., Luo, Z., Hu, Y., Peng, X., Lv, J., Zhao, S., Feng, J., Huang, G., Wan, Q.L., et al. (2021). MiniCAFE, a CRISPR/Cas9-based compact and potent transcriptional activator, elicits gene expression in vivo. *Nucleic Acids Res.* *49*, 4171–4185. <https://doi.org/10.1093/nar/gkab174>.
49. Xu, L., Zhao, L., Gao, Y., Xu, J., and Han, R. (2017). Empower multiplex cell and tissue-specific CRISPR-mediated gene manipulation with self-cleaving ribozymes and tRNA. *Nucleic Acids Res.* *45*, e28. <https://doi.org/10.1093/nar/gkw1048>.
50. Chan, K.Y., Jang, M.J., Yoo, B.B., Greenbaum, A., Ravi, N., Wu, W.L., Sánchez-Guardado, L., Lois, C., Mazmanian, S.K., Deverman, B.E., and Gradinaru, V. (2017). Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. *Nat. Neurosci.* *20*, 1172–1179. <https://doi.org/10.1038/nn.4593>.
51. Goertsen, D., Flytzanis, N.C., Goeden, N., Chuapoco, M.R., Cummins, A., Chen, Y., Fan, Y., Zhang, Q., Sharma, J., Duan, Y., et al. (2021). AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. *Nat. Neurosci.* *25*, 106–115. <https://doi.org/10.1038/s41593-021-00969-4>.

**OMTM, Volume 26**

**Supplemental information**

**PAM-flexible dual base editor-mediated random  
mutagenesis and self-activation  
strategies to improve CRISPRa potency**

**Cia-Hin Lau, Siping Huang, Raymond H.W. Lam, and Chung Tin**



**Supplementary Figure S1. Generation of VP64-mutated clones from HEK293FT C2.8 cells.** These GFP-positive cells are expressing CRISPRa (pTK-dSaCas9-VP64-2A-GFP-spA-pU6-sgRNA) that may carry mutated VP64 transgene.

**Table S1. Primers used for donor pTK-dSaCas9-VP64-2A-GFP-pU6-sgRNA construction**

Primer sequence (5' to 3') (forward, FP; reverse, RP)	Amplicon size (bp)	Description
FP: CACC GACTCGGGCGGGTCGCGCGCCC RP: AAAC GGGCGCGCGACCCGCCCGAGTC	-	for designing sgRNA of CRISPRa to target TK promoter
FP: AAAA TCTAGA AAAA CTCGAG AAATGAGTCTTCGGACCTCGC RP: AAAA ACCGGT TTAAGCGGGTCGCTGCAGGGT	753	PCR TK promoter with added XbaI and XhoI sites PCR TK promoter with added AgeI site
FP: AAAA TCTAGA TGCTTTCTCTGACCAGCATTCTCTCC RP: AAAA CTCGAG CTGTCCCTAGTGGCCCCACTGTG	814	PCR left homology arm from genomic AAVS1 of HEK293FT
FP: AAAA GCGGCCGC GATTGGTGACAGAAAAGCCCCATC RP: AAAA GCGGCCGC AGAGCAGAGCCAGGAACCCCTG	821	PCR right homology arm from genomic AAVS1 of HEK293FT
FP: GCATATACGATACAAGGCTGTTAGAGAG	-	for sequencing pU6-sgRNA

**Table S2. Primers used for knock-in of donor pTK-CRISPRa-GFP into genomic *AAVS1* locus**

Primer sequence (5' to 3') (forward, FP; reverse, RP)	Amplicon size (bp)	Description
FP: CACC GGGGCCACTAGGGACAGGAT RP: AAAC ATCCTGTCCCTAGTGGCCCC	-	for designing sgRNA of SpCas9 to target genomic <i>AAVS1</i> locus
FP: CGCGATCACATGGTCCTGCT RP: CCAAGCAGTCACCCACAGTTG	1.5k	for verifying targeted integration of pTK-CRISPRa into genomic <i>AAVS1</i> locus
FP: CTGAACGCCCATCTGGACATCAC RP: CGCTCCTGGACGTAGCCTTCG	1076	PCR dSaCas9-VP64-2A-GFP
FP: AAATGAGTCTTCGGACCTCGC RP: GTAGCCCACGCTGGTGATGC	867	PCR pTK-dSaCas9
FP: GTAGCCCACGCTGGTGATGC	-	for sequencing HL( <i>AAVS1</i> ) and pTK
FP: GACAATCGCCTCCAAGACCCAG	-	for sequencing VP64-2A-GFP
FP: GCATATACGATACAAGGCTGTTAGAGAG	-	for sequencing pU6-sgRNA



**Table S3. Primers used for VP64 mutagenesis**

Primer sequence (5' to 3') (forward, FP; reverse, RP)	Amplicon size (bp)	Description
FP: CACC GTCAAGGTCAAATCATCGA RP: AAAC TCGATGATTTTGACCTTGAC	-	for designing sgRNA-1 of base editors to target VP64
FP: CACC GTCGAGGTCAAAGTCATCAA RP: AAAC TTGATGACTTTGACCTCGAC	-	for designing sgRNA-2 of base editors to target VP64
FP: CACC GACTTTGACCTCGACATGCT RP: AAAC AGCATGTCGAGGTCAAAGTC	-	for designing sgRNA-3 of base editors to target VP64
FP: CACC GTCCAGGTCAAATCATCAA RP: AAAC TTGATGATTTGACCTGGAC	-	for designing sgRNA-4 of base editors to target VP64
FP: CACC GGACGGGCTGACGCATTGGA RP: AAAC TCCAATGCGTCAGCCCGTCC	-	for designing sgRNA-5 of base editors to target VP64
FP: CACC GCTGACGCATTGGACGATTT RP: AAAC AAATCGTCCAATGCGTCAGC	-	for designing sgRNA-6 of base editors to target VP64
FP: CACC GATCTGGATATGCTGGGAAG RP: AAAC CTTCCAGCATATCCAGATC	-	for designing sgRNA-7 of base editors to target VP64
FP: CACC GACCTTGACATGCTTGGTTC RP: AAAC GAACCAAGCATGTCAAGGTC	-	for designing sgRNA-8 of base editors to target VP64
FP: CACC GCCCTTGATGACTTTGACCT RP: AAAC AGGTCAAAGTCATCAAGGGC	-	for designing sgRNA-9 of base editors to target VP64
FP: CACC GACTTTGACCTCGACATGCT RP: AAAC AGCATGTCGAGGTCAAAGTC	-	for designing sgRNA-10 of base editors to target VP64
FP: CACC GACCTCGACATGCTCGGCAG RP: AAAC CTGCCGAGCATGTCGAGGTC	-	for designing sgRNA-11 of base editors to target VP64
FP: CACC GCCCTTGATGATTTGACCT RP: AAAC AGGTCAAAGTCATCAAGGGC	-	for designing sgRNA-12 of base editors to target VP64
FP: CACC GTTAATCAGCATGTCCAGGT RP: AAAC ACCTGGACATGCTGATTAAC	-	for designing sgRNA-13 of base editors to target VP64
FP: CACC GTCCAGGTCAAATCATCAA RP: AAAC TTGATGATTTGACCTGGAC	-	for designing sgRNA-14 of base editors to target VP64
FP: CACC GAAATCATCAAGGGCGTCAC RP: AAAC GTGACGCCCTTGATGATTTTC	-	for designing sgRNA-15 of base editors to target VP64
FP: CACC GTCGAGGTCAAAGTCATCAA RP: AAAC TTGATGACTTTGACCTCGAC	-	for designing sgRNA-16 of base editors to target VP64
FP: CACC GTCAAGGTCAAATCATCGA RP: AAAC TCGATGATTTTGACCTTGAC	-	for designing sgRNA-17 of base editors to target VP64
FP: CACC GTCATCAAGGGCATCCGAAC RP: AAAC GTTCGGATGCCCTTGATGAC	-	for designing sgRNA-18 of base editors to target VP64
FP: CACC GGCATCCGAACCAAGCATGT RP: AAAC ACATGCTTGGTTCGGATGCC	-	for designing sgRNA-19 of base editors to target VP64
FP: CACC GAACCAAGCATGTCAAGGTC RP: AAAC GACCTTGACATGCTTGGTTC	-	for designing sgRNA-20 of base editors to target VP64
FP: CACC GTCAAATCATCGAGGGCGT RP: AAAC ACGCCCTCGATGATTTTGAC	-	for designing sgRNA-21 of base editors to target VP64
FP: CACC GTCACCTCCAGCATATCCA RP: AAAC TGGATATGCTGGGAAGTGAC	-	for designing sgRNA-22 of base editors to target VP64
FP: CTGAACGCCCATCTGGACATCAC RP: CGCTCCTGGACGTAGCCTTCG	1076	PCR VP64 from genomic DNA of CRISPRa-inserted cells for sequencing
FP: GACATCACCTACCGGAGTACCTG RP: CGCTCCTGGACGTAGCCTTCG	-	for sequencing VP64
RP: CGCTCCTGGACGTAGCCTTCG	-	for sequencing VP64

**Table S4. Primers used for pAAV-CMV-dSaCas9-ΔVP64 construction in luciferase reporter experiments**

Primer sequence (5' to 3') (forward, FP; reverse, RP)	Amplicon size (bp)	Description
FP: AAAA TCTAGA TCCGCGTTACATAACTTACGG RP: AAAA ACCGGT AGCTCTGCTTATATAGACCTCCCA	508	PCR CMV with added XbaI site PCR CMV with added AgeI site
FP: CACC GACTCGGGCGGGTTCGCGCGCCC RP: AAAC GGGCGCGCGACCCGCCGAGTC	-	for designing sgRNA-1 of CRISPRa to target TK promoter
FP: CACC GCTCCTGCAGTCCCTCGCGCCT RP: AAAC AGGCGCGAGGACTGCAGGAGC	-	for designing sgRNA-2 of CRISPRa to target TK promoter
FP: CACC GCGAGGACTGCAGGAGCTTCA RP: AAAC TGAAGCTCCTGCAGTCCCTCGC	-	for designing sgRNA-3 of CRISPRa to target TK promoter
FP: CACC GCAAACGCGAGCAACGGGCCAC RP: AAAC GTGGCCCGTTGCTCGCGTTTGC	-	for designing sgRNA-4 of CRISPRa to target TK promoter
FP: CACC GTTCAATTACAGCTCTTAAGGC RP: AAAC GCCTTAAGAGCTGTAATTGAAC	-	for designing sgRNA-5 of CRISPRa to target TK promoter
FP: CACC GCCGCGGCGGCGACGGGCTCG RP: AAAC CGAGCCCGTCGCCGCCGCGGC	-	for designing sgRNA-6 of CRISPRa to target TK promoter
FP: CACC GGAGACCTTCTGCGGGACGAG RP: AAAC CTCGTCCCGCAGAAGGTCTCC	-	for designing sgRNA-7 of CRISPRa to target TK promoter
FP: CACC GCCCGACTGCATCTGCGTGT RP: AAAC ACACGCAGATGCAGTCGGGGC	-	for designing sgRNA-8 of CRISPRa to target TK promoter
FP: CACC GCGCGCGACCCGCCGAGT RP: AAAC ACTCGGGCGGGTCGCCGCGCC	-	for designing sgRNA of CRISPR/Cas9 to knockout CRISPRa activity
FP: AAAA GGATCC GGACGGGCTGACGCATTGG RP: AAAA GAATTC TTA GTTAATCAGCATGTCCAGGTCCG	168	PCR VP64 with added BamHI site PCR VP64 with added EcoRI site and stop codon (only for PCR D1, M12, S13, D4, CA8.1, CA8.15, CA10.11, and CA18.14 of VP64 mutants)
FP: AAAA GGATCC GGACGGGCTGACGCATTGG RP: AAAA GAATTC TTA GTTAATCAGCATGTCCGGGTCCG	90 or 129	PCR VP64 with added BamHI site PCR VP64 with added EcoRI site and stop codon (only for PCR M3 and S11 of VP64 mutants)
FP: AAAA GGATCC GGACGGGCTGACGCATTGG RP: AAAA GAATTC TTA GTTAATCAGCATGTTTAGGTCCG	159 or 156	PCR VP64 with added BamHI site PCR VP64 with added EcoRI site and stop codon (only for PCR S4 and S9 of VP64 mutants)
FP: AAAA GGATCC GGACGGGCTGACGCATTGG RP: AAAA GAATTC TTA GTTAATCAGCATGTCTAGGTTG	168	PCR VP64 with added BamHI site PCR VP64 with added EcoRI site and stop codon (only for PCR S1 of VP64 mutant)
FP: AAAA GGATCC GGACGGGCTGACGCATTGG RP: AAAA GAATTC TTA GTTAATCAGCATGTGCGGGTCCG	134	PCR VP64 with added BamHI site PCR VP64 with added EcoRI site and stop codon (only for PCR M5 of VP64 mutant)
FP: AAAA GGATCC GGACGGGCTGACGCATTGG RP: AAAA GAATTC TTA GTTAATCAGCATGTGAGGGCGTC	75	PCR VP64 with added BamHI site PCR VP64 with added EcoRI site and stop codon (only for PCR S2 of VP64 mutant)
FP: AAAA GGATCC GGACGGGCTGACGCATTGG RP: AAAA GAATTC TTA GTTAATCAGCATGTTCAGGTCCG	168	PCR VP64 with added BamHI site PCR VP64 with added EcoRI site and stop codon (only for PCR A2 of VP64 mutant)
FP: AAAA GGATCC GGACGGGCTGACGCATTGG RP: AAAA GAATTC TTA GTTAATCAGCATGTCCGGGTGG	168	PCR VP64 with added BamHI site PCR VP64 with added EcoRI site and stop codon (only for PCR M6 of VP64 mutant)
FP: AAAA GGATCC GGACGGGCTGACGCATTGG RP: AAAA GAATTC TTA GTTAATCAGCATGTGAGGTCCG	168	PCR VP64 with added BamHI site PCR VP64 with added EcoRI site and stop codon (only for PCR A3 of VP64 mutant)
FP: GACATCACCTACCGCGAGTACCTG	-	for sequencing ΔVP64 in pAAV-CMV-dSaCas9-ΔVP64

---

RP: CAGGGCGCGTACTATGTTGC

-

for sequencing  $\Delta$ VP64 and pU6-sgRNA in pAAV-CMV-dSaCas9-  
 $\Delta$ VP64

---

**Table S5. Primers used for pAAV-CMV-dSaCas9-ΔVP64 construction in endogenous gene modulation experiments**

Primer sequence (5' to 3') (forward, FP; reverse, RP)	Amplicon size (bp)	Description
FP: AAAA TCTAGA TCCGCGTTACATAACTTACGG RP: AAAA ACCGGT AGCTCTGCTTATATAGACCTCCCA	508	PCR CMV with added XbaI site PCR CMV with added AgeI site
FP: AAAA GGATCC GGACGGGCTGACGCATTGG RP: AAAA GAATTC TTA GTTAATCAGCATGTTCCAGGTCC	168	PCR VP64 with added BamHI site PCR VP64 with added EcoRI site and stop codon (only for PCR A2 of VP64 mutant)
FP: AAAA GGATCC GGACGGGCTGACGCATTGG RP: AAAA GAATTC TTA GTTAATCAGCATGTTTAGGTCC	159	PCR VP64 with added BamHI site PCR VP64 with added EcoRI site and stop codon (only for PCR S4 of VP64 mutants)
FP: AAAA GGATCC GGACGGGCTGACGCATTGG RP: AAAA GAATTC TTA GTTAATCAGCATGTCCAGGTCC	168	PCR VP64 with added BamHI site PCR VP64 with added EcoRI site and stop codon (only for PCR CA10.11 of VP64 mutants)
FP: CACC GGGGGCAGGGGCGCCGAGGGCG RP: AAAC CGCCCTCGGCGCCCTGCCCC	-	for designing sgRNA site-10 of CRISPRa to target human <i>KLOTHO</i> promoter
FP: CACC GGC GCGCTCCGCTAGGGCCCGG RP: AAAC CCGGGCCCTAGCGGAGCGCGCC	-	for designing sgRNA site-11 of CRISPRa to target human <i>KLOTHO</i> promoter
FP: CACC GGGAATTCGCCGTGCGCTGAA RP: AAAC TTCAGCGCACGGCGAAGTTCCC	-	for designing sgRNA site-12 of CRISPRa to target human <i>KLOTHO</i> promoter
FP: CACC GCGGGCCGCCCAATTTCCCGC RP: AAAC GCGGAAATTGGGGCGGCCGCC	-	for designing sgRNA site-9 of CRISPRa to target human <i>SIRT6</i> promoter
FP: CACC GCATGCGCCTTGCCGTGGGAGG RP: AAAC CCTCCCACGGCAAGGCGCATGC	-	for designing sgRNA site-10 of CRISPRa to target human <i>SIRT6</i> promoter
FP: CACC GGACAGCAGGGACCCAGCCT RP: AAAC AGGCTGGGGTCCCTGCTGTCC	-	for designing sgRNA site-11 of CRISPRa to target human <i>SIRT6</i> promoter
FP: CACC GCGTCAGCCCCGGCGGGGTG RP: AAAC CACCCGCGCCGGGGCTGACGC	-	for designing sgRNA site-1 of CRISPRa to target human <i>NFE2L2</i> promoter
FP: CACC GGGGCGGGAAGGGACTGCCAGC RP: AAAC GCTGGCAGTCCCTTCCC GCCC	-	for designing sgRNA site-2 of CRISPRa to target human <i>NFE2L2</i> promoter
FP: CACC GGGCAGTTGGCAGTGGCACGGT RP: AAAC ACCGTGCCACTGCCAACTGCC	-	for designing sgRNA site-3 of CRISPRa to target human <i>NFE2L2</i> promoter
FP: GCATATACGATACAAGGCTGTTAGAGAG	-	for sequencing pU6-sgRNA

**Table S6. Primers used for AAV titers**

Primer sequence (5' to 3') (forward, FP; reverse, RP)	Amplicon size (bp)	Description
6-FAM-CACCACGCCGAGGACGCCCTGA-ZEN/Iowa	-	probe specific to dSaCas9
FP: TCCATCAATGGCGGCTTCA RP: GGCCTTGCCAGTTTCTTCCA	150	quantify the copies number of dSaCas9 DNA

**Table S7. Primers used for qRT-PCR and TaqMan qPCR**

Primer sequence (5' to 3') (forward, FP; reverse, RP)	Amplicon size (bp)	Description
FP: ACCATCTTCCAGGAGCGAGA RP: TGGCATGGACTGTGGTCATG	319	qPCR mRNA expression level of human <i>GAPDH</i>
FP: ACCAAGAGAGATGATGCCAAATA RP: CCACTCGAAACCATCCATGA	132	qPCR mRNA expression level of human <i>KLOTHO</i>
FP: CCCACGGAGTCTGGACCAT RP: CTCTGCCAGTTTGTCCCTG	194	qPCR mRNA expression level of human <i>SIRT6</i>
FP: CACATCCAGTCAGAAACCAAGTGG RP: GGAATGTCTGCGCCAAAAGCTG	112	qPCR mRNA expression level of human <i>NFE2L2</i>